Biohaven Ltd. Income Statement
BHVN / Health Care|5 years of annual SEC 10-K data (FY2020-FY2024)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 5 fiscal years. All figures from audited SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.10 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| SG&A Expense | $89.2M | $62.8M | $130.9M | $37.4M | $16.0M |
| R&D Expense | $795.9M | $373.3M | $437.1M | $181.5M | $98.5M |
| Operating Income | -$885.1M | -$436.1M | -$567.9M | -$218.9M | -$114.5M |
| Income Tax | $735.0K | -$1.4M | $438.0K | $1.4M | $0 |
| Net Income | -$846.4M | -$408.2M | -$570.3M | -$213.8M | -$118.7M |
| EPS (Basic) | -$9.28 | -$5.73 | -$12.75 | -$5.43 | -$3.01 |
| EPS (Diluted) | -$9.28 | -$5.73 | -$12.75 | -$5.43 | -$3.01 |
| Shares Outstanding | 91.2M | 71.2M | 44.7M | 39.4M | 39.4M |